Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
Appointed director

Inmune Bio, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/08/2019 8-K Quarterly results
09/23/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Session 3: Therapeutics: State of the Field Presentation Title: A Biomarker-Directed Approach to Targeting Inflammation in Alzheimer’ s Patients Time and Date: 5:10 PM – 5:30 PM, Sept. 25 Location: Hyatt Regency Sydney, Australia"
09/18/2019 8-K Quarterly results
09/12/2019 4 Lowdell Mark William (Chief Scientific Officer) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 2,918 shares @ $6.2298, valued at $18.2k
09/12/2019 8-K Quarterly results
09/12/2019 8-K Quarterly results
09/09/2019 8-K Quarterly results
09/04/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference"
08/27/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Investor Fact Sheet"
08/22/2019 4 Juda Scott (Director) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 2,500 shares @ $6, valued at $15k
Bought 2,500 shares @ $6, valued at $15k
08/21/2019 4 Moss David J (CFO, Treasurer & Secretary) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 77 shares @ $5.65, valued at $435.1
Bought 239 shares @ $5.65, valued at $1.4k
Bought 2,000 shares @ $5.65, valued at $11.3k
Bought 72 shares @ $5.65, valued at $406.8
Bought 236 shares @ $5.65, valued at $1.3k
Bought 376 shares @ $5.65, valued at $2.1k
08/21/2019 4 Tesi Raymond Joseph (President & CEO) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 100 shares @ $5.96, valued at $596
Bought 100 shares @ $5.9239, valued at $592.4
Bought 1,000 shares @ $6.0308, valued at $6k
08/16/2019 3 Form 3 - Initial statement of beneficial ownership of securities:
08/15/2019 8-K Quarterly results
08/13/2019 8-K Quarterly results
08/12/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/09/2019 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/09/2019 8-K Quarterly results
08/09/2019 10-Q Quarterly Report for the period ended June 30, 2019
08/07/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer"
08/01/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit La Jolla, CA. – Aug. 1, 2019 – INmune Bio, Inc. , an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that RJ Tesi, M.D., co-founder and CEO, will present at the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit, taking place in Boston from Aug. 5 through Aug. 9. “We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and other effective cancer treatments,” said Dr. Tesi. “I am delighted to have the chance to present with some of the most prominent leaders in the immuno-oncology community.” Below is a schedule ..."
07/30/2019 8-K Quarterly results
07/29/2019 PRE 14A Form PRE 14A - Other preliminary proxy statements:
07/29/2019 EFFECT Form EFFECT - Notice of Effectiveness:
07/26/2019 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/18/2019 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
07/09/2019 8-K Other Events
07/03/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Co-Founder and CEO Presents at Maxim Group’s Conference on Alzheimer’s Disease La Jolla, CA – July 3, 2019 – INmune Bio, Inc. , an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that R.J. Tesi, M.D., the company’s co-founder and CEO, presented at the Maxim Group ’s conference on Alzheimer’s disease on June 26 in New York. During his presentation, Dr. Tesi addressed how INmune Bio’s drug candidate XPro1595 targets microglial activation and neuroinflammation to treat Alzheimer’s, which may be a key driver in the disease. During the conference, titled “ Alzheimer's Disease – What's Next? Treating Alzheimer's in a Post-Amyloid World ,” Dr. Tesi discussed INmune Bio’s novel approach to treating Alzheimer..."
07/03/2019 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/03/2019 EFFECT Form EFFECT - Notice of Effectiveness:
06/28/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Announces Publication of Data on INKmune Primed NK cells in Peer-Reviewed Journal PLOS ONE La Jolla, CA – June 27, 2019 – INmune Bio, Inc. , an immunotherapy company developing treatments that harness the patient’s innate immune system to fight disease, announced today that the peer-reviewed open access scientific journal PLOS ONE published an article titled, “Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures,” summarizing the different effects between NK cell activation in response to tumor cells and cytokine-mediated activation. Co-authored by Dr. Mark Lowdell, Chief Scientific Officer and co-founder at INmune Bio, the paper defines the response of natural killer cells following their encounters with tumor cells an..."
06/26/2019 8-K Investor presentation
Docs: "Investor Presentation"
06/24/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentation"
06/17/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Feature in NetworkNewsWire Broadcast June 11, 2019"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy